Illumina, Inc. has launched the Billion Cell Atlas, a large-scale genetic perturbation dataset designed to serve as foundational infrastructure for artificial intelligence-enabled drug discovery. Announced alongside strategic collaborations with AstraZeneca, Merck, and Eli Lilly and Company, the platform leverages CRISPR-based genome editing and single-cell RNA sequencing across more than 200 disease-relevant cell lines. This marks […]
Illumina, Inc. has officially launched Connected Multiomics, a cloud-native software platform designed to unify and analyze complex biological data across multiple omic modalities including genomics, transcriptomics, proteomics, and spatial biology. The tool is now widely available after a year-long early access program involving over 40 research groups. Positioned as a user-friendly yet technically powerful analysis […]
Illumina, Inc. and MyOme, Inc. have announced a new strategic collaboration, including an equity investment by Illumina to support MyOme’s upcoming Proactive Health (MPH) Trial. The large-scale clinical study, expected to begin in 2026, will evaluate the impact of artificial intelligence-integrated whole-genome sequencing on chronic disease prevention and cost savings across the U.S. healthcare system. […]
